Core Insights - Madison Large Cap Fund underperformed the S&P 500 Index, decreasing by 2.2% in Q3 2025 compared to an 8.1% gain for the index, primarily due to a market focus on short-term profits [1] - The fund's top five contributors included Lowe's Companies, Inc., which benefited from an improving U.S. housing market and announced the acquisition of Foundation Building Materials [3] Fund Performance - Madison Large Cap Fund's performance in Q3 2025 was significantly lower than the S&P 500 Index, indicating challenges in the current market environment [1] - The fund's focus on long-term investments may have contributed to its underperformance relative to the benchmark [1] Company Focus: Lowe's Companies, Inc. - Lowe's Companies, Inc. experienced a one-month return of -3.21% and a 52-week loss of 13.66%, with its stock closing at $233.03 on November 10, 2025, and a market capitalization of $130.689 billion [2] - The company was highlighted as a top contributor to the fund's performance, with improvements linked to a thawing U.S. housing market and growth opportunities from its acquisition of Foundation Building Materials [3] Hedge Fund Interest - Lowe's Companies, Inc. was held by 75 hedge fund portfolios at the end of Q2 2025, an increase from 68 in the previous quarter, indicating growing interest among institutional investors [4] - Despite this interest, the analysis suggests that certain AI stocks may offer greater upside potential compared to Lowe's [4]

Core Insights - Madison Investments' "Madison Large Cap Fund" underperformed in Q3 2025, decreasing by 2.2% compared to an 8.1% gain for the S&P 500 Index, primarily due to a market focus on short-term profits [1] - The fund's top five contributors included The TJX Companies, which performed well amid economic uncertainty, leading to strong revenue and profit growth [3] Company Performance - The TJX Companies, Inc. (NYSE:TJX) had a one-month return of 1.82% and a 52-week gain of 22.42%, closing at $146.72 per share with a market capitalization of $163.29 billion on November 10, 2025 [2] - The TJX Companies was highlighted as a top contributor for the Madison Large Cap Fund in Q3 2025, benefiting from its value-based retail stores resonating with consumers [3] Hedge Fund Interest - The TJX Companies was held by 73 hedge fund portfolios at the end of Q2 2025, a slight decrease from 77 in the previous quarter, indicating a stable interest among hedge funds [4]

Core Insights - Madison Large Cap Fund underperformed in Q3 2025, decreasing by 2.2% compared to an 8.1% gain for the S&P 500 Index, primarily due to a market focus on short-term profits [1] - The fund's top five contributors included Parker-Hannifin Corporation, which reported strong results in its aerospace segment and company-wide margin improvements [3] Company Performance - Parker-Hannifin Corporation (NYSE:PH) achieved a one-month return of 14.14% and a 52-week gain of 20.21%, closing at $840.63 per share with a market capitalization of $106.076 billion on November 10, 2025 [2] - In the first quarter of fiscal 2026, Parker-Hannifin reported record sales of $5.1 billion, reflecting an organic growth of 5% [4] Investment Sentiment - Despite its strong performance, Parker-Hannifin is not among the 30 most popular stocks among hedge funds, with 51 hedge fund portfolios holding the stock at the end of Q2 2025, unchanged from the previous quarter [4] - There is a belief that certain AI stocks may offer greater upside potential and carry less downside risk compared to Parker-Hannifin [4]

Core Insights - Pelican Bay Capital Management (PBCM) reported a 7.8% return for its Concentrated Value Strategy in Q3 2025, outperforming the Russell 1000 Value Index which returned 5.3% [1] - Year-to-date, PBCM's fund returned 11.2%, slightly below the index's 11.6% [1] Company Overview: Elevance Health, Inc. (NYSE:ELV) - Elevance Health, Inc. is a health benefits company with over 45 million members, operating under brands like Anthem Blue Cross Blue Shield and Wellpoint [3] - The company has a competitive advantage through its in-house pharmacy benefit manager, Carelon [3] Stock Performance - Elevance Health's stock experienced a one-month return of -10.04% and a 52-week decline of 24.81% [2] - As of November 7, 2025, Elevance Health's stock closed at $317.78, with a market capitalization of $70.623 billion [2] Financial Performance - In Q3 2025, Elevance Health reported operating revenue of $50.1 billion, marking a 12% year-over-year increase [4] - Despite the revenue growth, the stock is not favored among hedge funds, with a decrease in holdings from 75 to 67 portfolios [4] Investment Perspective - While Elevance Health is recognized for its potential, the company is compared unfavorably to certain AI stocks that are perceived to offer greater upside potential and lower downside risk [4]

Core Insights - Norwegian Cruise Line Holdings Ltd. (NCLH) is recognized as one of the best low-priced stocks to buy according to analysts, with a record total revenue of $2.9 billion for Q3 2025, marking a 5% increase compared to Q3 2024 [1][2]. Financial Performance - The company reported an adjusted EPS of $1.20 for Q3 2025, exceeding the guidance of $1.14 and reflecting a 17% increase from Q3 2024 [2]. - For FY 2025, NCLH anticipates an adjusted EBITDA of approximately $2.72 billion [4]. Analyst Ratings and Expectations - Analyst Stephen Grambling from Morgan Stanley maintained a "Hold" rating on NCLH with a price target of $27.00, noting that while the company surpassed its Q3 guidance, the results did not meet the firm's or consensus expectations [3]. - The Q4 2025 guidance was set lower, indicating potential challenges in pricing power, with expected net yield on a constant currency basis between approximately 3.5% and 4.0% [3]. Strategic Focus and Market Position - NCLH continues to benefit from its strategic focus on Caribbean itineraries, which are attracting more families to the brand, with expectations of this trend continuing into 2026 [4]. - The total revenue growth was driven by higher Capacity Days and strong demand, although it was partially offset by lower air program participation due to changes in itinerary mix [4].

Core Insights - Merck & Co., Inc. (NYSE:MRK) is recognized as one of the 15 Best DRIP Stocks to Own Right Now [1] - Morgan Stanley has raised the price target for Merck from $98 to $100 while maintaining an Equal Weight rating, citing strong third-quarter results driven by one-time items and robust performance of Januvia, despite Keytruda and Winrevair sales falling short of expectations [2] - Merck's Q3 2025 results showed Keytruda sales increased by 10% to $8.1 billion, and Animal Health sales grew by 9% to $1.6 billion, contributing to an overall revenue of $17.28 billion, which is nearly a 4% increase from the previous year [3] Financial Performance - For 2025, Merck expects worldwide sales to be between $64.5 billion and $65.0 billion and has adjusted its non-GAAP EPS guidance to a range of $8.93 to $8.98 [3] - Analyst Flynn projects Merck's EPS for 2026 to be $9.44, anticipating solid top-line growth driven by new product launches, although operating expenses are expected to accelerate [2] Company Overview - Merck is a global healthcare company focused on delivering innovative medicines, vaccines, biologic therapies, and animal health products [4]

Core Insights - AT&T Inc. is recognized as one of the 15 Best DRIP Stocks to Own Right Now [1] - TD Cowen raised AT&T's price target from $32 to $33, maintaining a Hold rating due to solid subscriber growth [2] - The company reaffirmed its near-term and long-term guidance, although there are concerns regarding ARPU, wireless margins, and competition from Verizon [3] Financial Performance - AT&T reported mixed third-quarter results for 2025, with revenue increasing by 2% year-over-year to $30.7 billion [4] - Operating cash flow remained steady at $10.2 billion, while capital expenditures totaled $4.9 billion, and overall capital investment reached $5.3 billion [4] - Free cash flow rose to $4.9 billion from $4.6 billion a year earlier [4] Guidance and Projections - For the full year, AT&T reiterated its guidance, projecting low-single-digit growth in consolidated service revenue [5] - Mobility service revenue is expected to grow by 3% or more, with mid-to-high-teens growth in consumer fiber broadband revenue [5] - Adjusted EBITDA is anticipated to grow by 3% or more, with mobility EBITDA around 3% [5] Company Overview - AT&T is a leading telecommunications conglomerate providing wireless (5G) and wireline (fiber) services, along with business solutions and entertainment offerings [6]

Core Insights - PepsiCo, Inc. (NASDAQ:PEP) has been recognized as one of the 15 Best DRIP Stocks to Own Right Now, highlighting its attractiveness for dividend reinvestment strategies [1] - DZ Bank upgraded PepsiCo from Hold to Buy, setting a price target of $167, reflecting confidence in the company's future performance [2] - The company reported a strong third-quarter revenue of $23.9 billion, representing a 2.7% year-over-year increase and exceeding analyst expectations by approximately $90 million [3] Financial Performance - PepsiCo's third-quarter revenue reached $23.9 billion, marking a 2.7% increase compared to the previous year [3] - The company anticipates low single-digit growth in organic revenue looking ahead to 2025 [3] - PepsiCo plans to return about $8.6 billion to shareholders, which includes $7.6 billion in dividends and $1 billion in share repurchases [3] Dividend Stability - PepsiCo has increased its dividend for 53 consecutive years, demonstrating a strong commitment to returning value to shareholders [4] - The company operates as a global leader in the food and beverage industry, with a diverse portfolio of well-known brands such as Pepsi-Cola, Lay's, and Gatorade [4]

Core Insights - The Sherwin-Williams Company (NYSE:SHW) has been recognized as one of the 15 Best DRIP Stocks to Own Right Now, indicating strong investor interest and confidence in its performance [1] - Mizuho has raised its price target for Sherwin-Williams to $400 from $385, maintaining an Outperform rating, which reflects positive sentiment regarding the company's market positioning and performance [2] - For Q3 2025, Sherwin-Williams reported a 3.2% increase in consolidated net sales to $6.36 billion, with a 3.6% rise in sales from stores open for more than a year, and a 3.3% increase in net income to $833.1 million, representing 13.1% of total sales [3] Financial Performance - The company expanded its adjusted EBITDA margin and adjusted diluted EPS during the quarter, showcasing operational efficiency [3] - Sherwin-Williams returned $864 million to shareholders through dividends and share buybacks, highlighting its commitment to shareholder value [3] Leadership Changes - Benjamin E. Meisenzahl will become the Chief Financial Officer starting January 1, 2026, bringing over two decades of experience with the company [4] - Meisenzahl has previously served as Senior Vice President of Finance, indicating continuity in leadership [4] Market Position - Sherwin-Williams is recognized as a global leader in paints and coatings, serving a diverse range of professional, industrial, commercial, and retail customers worldwide [4]

Core Insights - AbbVie Inc. has been recognized as one of the 15 Best DRIP Stocks to Own Right Now [1] - Piper Sandler raised AbbVie's price target from $284 to $289, maintaining an Overweight rating due to stronger long-term expectations for Skyrizi and improved forecasts for the Neuroscience division [2] - AbbVie's third-quarter 2024 results showed a total revenue of $15.7 billion, a 9.1% year-over-year increase, with significant growth in the immunology segment [3] Financial Performance - The immunology segment generated earnings of $7.89 billion, reflecting an 11.9% increase on a reported basis and an 11.2% increase on an operational basis [3] - Global sales of Skyrizi increased by 46.8% to $4.71 billion, while Rinvoq revenues rose by 35.3% to $2.18 billion [3] - Humira revenues decreased by 55.4% to $993 million due to competition from biologic similar products [3] Company Overview - AbbVie Inc. is a research-driven biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines and therapies [4]